Drug pipelines are changing and sponsors are focusing on highly targeted therapies. To do that effectively, investigators must rely on genetic testing.
But that’s easier said than done.
Historically a Phase III trial would collect about a million data points; with genetic testing that’s increased to 3 to 5 million data points. And to enroll the right patients, genetic testing often must be done before someone enters a trial.
That volume of highly complex data leaves many investigators struggling to explain results to patients. It can be daunting.
That’s where a new partnership between WCG and InformedDNA can help you.
Mark your calendar for Aug. 23 when CenterWatch brings you a FREE virtual roundtable, featuring WCG’s Chief Medical Officer Lindsay McNair, InformedDNA’s Karmen Trzupek and Jill Johnston of WCG’s Site Management Group.
These three highly engaging genetic and trial experts will bring you the their best advice for thriving in this brave new clinical trial world.
Sign up now.
Who Will Benefit
Sign Up for FREE Below
Chief Medical Officer, WIRB-Copernicus Group (WCG)
Dr. McNair is Chief Medical Officer of the WIRB-Copernicus Group (WCG). She has consulted to numerous biopharma companies, providing medical guidance on clinical development strategies and study designs for new drug studies and medical oversight of all phases of clinical trials. She now oversees the physician team within the WCG IRBs, providing support to pharma/biotech companies on protocol design, regulatory compliance, human subject protection, and ethical policy development.
Director, Ocular and Rare Disease Genetics Services, InformedDNA
Karmen Trzupek MS CGC is Director, Ocular and Rare Disease Genetics Services for InformedDNA. A Certified Genetics Counselor, she has extensive experience with macular degeneration, Usher syndrome and other retinal diseases with a heritability component.
President, Site Activation, WCG Clinical Services
Jill Johnston is President, Site Activation, WCG Clinical Services, charged with developing strategy, driving the vision, and delivering for customers in clinical trial site identification, selection, and activation. With 25+ years in clinical research, Ms. Johnston is an expert in clinical business strategy, transformation, innovation, pharmaceutical efficiency, and clinical research operations.